CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation
← catalyst calendarNCT06355063 · readout in 134 d
Sponsored by Pulse Biosciences, Inc. (industry) · PLSE — their whole pipeline →. With Avania.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
6
Countries
Austria, Netherlands, Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-31 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atrial Fibrillation
- Surgery
- Ablation of Atrial Fibrillation
- Clamp Study
Intervention
- Device: CellFX® nsPFA™ Cardiac Surgery System
Primary outcomes
what the primary-completion date above is the date OFRate of acute major adverse events (MAEs)
measured Within 30 days post-ablation procedure
Number of Participants with acute electrical isolation of the bilateral pulmonary veins and left atrial box
measured Within 24 hours post-ablation procedure
Permalink · PLSE's whole pipeline · Catalyst calendar · Every registered study · What changed